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Abstract: Objectives : To test the ability of a multi-criteria decision analysis (MCDA) model 
to incorporate disparate data sources of varying quality along with clinical judgement in a 
benefit-risk assessment of six well-known pain-relief drugs.  Methods:  Six OTC analgesics 
were evaluated against three favourable effects and eight unfavourable effects by seven 
experts who specialise in the relief of pain, two in a two-day facilitated workshop whose 
input data and judgements were later peer-reviewed by five additional experts. Key findings: 
Ibuprofen salts & solubilised emerged with the best benefit-risk profile, followed by 
naproxen, ibuprofen acid, diclofenac, paracetamol, and aspirin. Conclusions: MCDA enabled 
participants to evaluate the OTC analgesics against a range of favourable and unfavourable 
effects in a group setting that enabled all issues to be openly aired and debated.   The model 
was easily communicated and understood by the peer reviewers, so the model should be 
comprehensible to physicians, pharmacists, and other health professionals 
Key words:  OTC analgesics, MCDA, group judgements, decision conferencing, pain relief 
1. Introduction: 
Providing safe and effective over-the-counter (OTC) medications for minor (non-serious) 
ailments is an increasingly important part of many healthcare systems. Simple analgesics are 
available without prescription in most countries worldwide for the symptomatic treatment of 
acute, self-limiting painful conditions [1, 2].   Recent EU data shows that 47% of consumers 
have used an OTC analgesic once per week in the last month [3]. No study has directly 
compared all these analgesic active ingredients and conventional meta-analyses cannot do 
full justice to the complex array of data on all their risks and benefits.  Most of the data 
relating to the efficacy, and most particularly, the safety of these medicines derives from 
clinical studies conducted in the prescription setting in chronic conditions and with higher 
doses used for more prolonged periods of time than in the OTC setting.  MCDA was 
employed as a novel approach to combining the available data across criteria to provide an 
explicit and succinct benefit-risk balance.  
In 2012 the European Medicines Agency (EMA, formerly the EMEA) updated the EU 
regulatory framework [4] with what are now 
considered amongst the most significant changes 
for the regulation of medicines in the EU since 
the establishment of the EMA in 1995.  The goal 
of this new legislation is to promote and 
improve the safety of medicines and facilitates 
the introduction and continual improvement of 
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benefit-risk evaluations.  
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) at their meeting on 25th 
June 2015 agreed in their work plan to focus on methodologies for the benefit-risk decision-
making process[5], highlighting the importance of robust, transparent and reproducible 
decision making when interpreting clinical data by groups of experts.  
Demonstrating how the positive and negative features of a medicine balance is difficult and 
largely subjective [6]. Computer-based models exist which analyse multiple criteria to assist 
with benefit-risk evaluations.  These models enable enhanced quality and consistency of 
decision making based on the interpretation of best evidence by experts. One such model 
provides the opportunity to review existing data and produce a multi-criteria decision analysis 
(MCDA). MCDA has already been used to assess benefit and risks of prescription drugs [7-
10] and the harms of psychoactive drugs [11, 12].  This study extends that research to over-
the-counter (OTC) analgesics.   
Analgesics vary considerably in terms of their relative efficacy and safety. Factors involved 
include the pharmacological and toxicological properties of individual drugs, their patterns of 
use, and patient-related factors [13, 14].
 
Making assessments of benefit and risk for the 
current range of simple OTC analgesics has not been easy. Reasons include: 
 decision-making methods have not been standardised,  
 results have not been easily reproducible by independent third parties,  
 there are a wide range of factors, confounders and biases that have to be considered, and  
 there is a degree of uncertainty in the interpretation of benefit and risk.  
Individual clinical studies and meta-analyses have investigated safety and tolerability 
outcomes or one or more measures of efficacy.  However, as far as the authors are aware, 
there is no single study comparing the overall benefit-risk ratios of these medicines. The aim 
of this MCDA was to assess and compare the relative benefit-risk balance of the most 
common single-active, oral systemic analgesics available over the counter (OTC) in the EU.  
2. Methods: 
2.1 Study Design:  
A group of scientific experts specialising in pain relief, consisting of independent experts 
from academia (authors KR and AM), as well as scientists from industry (authors AC, BN 
and OS), undertook a benefit-risk assessment of six well-known OTC pain-relief drugs: 
aspirin (analgesic dose), diclofenac potassium, ibuprofen acid, ibuprofen salts and solubilised 
formulations (ibuprofen S&S), paracetamol, and naproxen sodium. Experts were chosen 
based on their well-established clinical and scientific expertise and professional standing in 
pain relief to include a diversity of experience in analysing and interpreting data in the areas 
of efficacy and safety. 
The MCDA process was conducted over a two-day facilitated workshop held in Hull on the 
17
th
 – 18th September 2014.  A similar model developed in 2010 to analyse the harms of a 
range of drugs in the UK [11] was used as a starting point, and adapted to assess the overall 
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benefits and risks of each drug. A computer program, Hiview3, was used for data entry, 
analysis and visualisation [15]. A summary of the methodology is set out in Appendix 1. 
Although RB participants were present during this process, they did not participate in the 
construction of the Hiview model. Briefly, eight steps were followed to analyse and interpret 
the data [16]:  
1. establishing context with respect to the need for a robust benefit-risk assessment tool;  
2. agreeing on the products to be evaluated and producing definitions of these; 
3. agreeing on the criteria on which the products should be compared;  
4. scoring the products on each criterion;  
5. weighting the criteria;  
6. calculating weighted scores to give an overall index of the benefit-risk balance of each 
product; 
7. examining results and resolving any inconsistencies, and  
8. exploring the sensitivity of the indices to different assessments of scores and weights.  
The OTC analgesics to be evaluated were chosen based on the following characteristics.  
They should: 
 be indicated for patients over the age of 18 years for short-duration use in acute pain,  
 be available for purchase over the counter in the UK, and, to some extent, in Europe and 
rest of the world, 
 contain a single active ingredient, 
 be supported by robust publicly available data.  
Since the impact of solubility of ibuprofen on pharmacokinetics and analgesic efficacy is well 
established [2, 14, 17-19], ibuprofen S&S have been included separately from standard 
ibuprofen acid. Diclofenac potassium is a salt formulation designed for immediate release 
and is available OTC in some parts of the world and effective in acute pain [20], and was 
included, while diclofenac sodium available on prescription was not. The following OTC 
medicines were agreed to be considered by the group: aspirin (analgesic dose), diclofenac 
potassium, ibuprofen acid, ibuprofen S&S, paracetamol, and naproxen sodium. 
2.2 Criteria on which the products were compared  
The experts considered three benefits (favourable effects) and eight risks (unfavourable 
effects) for the chosen drugs, taking into account the intended use of these drugs for the 
symptomatic treatment of acute mild to moderate pain with lower doses than prescription 
doses for a short period of time. The eleven effects are shown in Figure 1, with the 
unfavourable effects grouped under adverse reactions and serious adverse reactions, plus 
overdose toxicity. 
[Insert Figure 1 about here] 
Favourable effects 
For OTC use, the desired characteristics of a good analgesic agent are providing good pain 
relief to a high proportion of subjects taking the medicine, speedy onset of action, and long 
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duration of action. Therefore, the three favourable effects of clinical relevance in the model 
were: 
 pain relief, proportion of patients suffering moderate to severe pain who report at least 
50% pain intensity reduction over 4-6 hours. This is the outcome generally recognised in 
systematic reviews and meta-analyses of single dose oral drugs in acute pain, and is the 
subject of a Cochrane overview review of OTC analgesics [14].  
 speed of onset:- time to perceptible pain relief in minutes. 
 duration of action:- time to remedication for 50% of the patients measured in hours. 
Unfavourable effects  
The unfavourable effects were categorised into 3 groups as adverse reactions, serious adverse 
reactions and overdose toxicity.   
Unfavourable Effects - Adverse Reactions 
Since analgesics are used at low doses and for short treatment periods in the OTC setting, 
only adverse reactions that may lead to treatment discontinuation of mild to moderate 
severity were considered. Thus, the incidence rates and severity of the following were 
included in the model: 
 skin reactions such as rashes, pruritus, 
 gastrointestinal (GI) complaints such as dyspepsia, nausea, vomiting and diarrhoea, 
flatulence, constipation, and abdominal pain,  
 hepatic reactions such as mild, reversible elevation of liver enzymes and mild reversible 
elevation in bilirubin. 
Unfavourable Effects - Serious Adverse Reactions:  
Adverse reactions that are life-threatening, lead to death, require hospitalisation or medical 
treatment, or result in persistent or significant disability are considered serious.  While these 
are rare (≥1/10,000 and <1/1000) to very rare (< 1/10,000) with OTC analgesics, the 
consequences might be devastating. Therefore, incidence rate and severity of the following 
four effects have been taken into account in the model: 
 GI effects such as GI ulceration, bleeding, melaena, haematemesis and perforation, 
 cardiovascular (CV) effects such as heart failure, hypertension, myocardial infarction and 
stroke 
 renal effects such as acute renal failure 
 severe allergic and hypersensitivity reactions such as anaphylaxis, Stevens - Johnson 
syndrome (SJS), Lyell’s syndrome (toxic epidermal necrolysis), asthma and 
bronchospasm.  
Unfavourable Effects - Overdose toxicity: 
While overdose is rare with these drugs, considering the wide availability and potentially life 
threatening consequences of toxicity in overdose; the extent, severity and nature of toxicity in 
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accidental or intentional overdose was included as an additional unfavourable effect in the 
model. 
The key references from which the evidence was sourced are summarised in Appendix 2.  
The final effects tree included 3 favourable and 8 unfavourable effects, shown in Figure 1.  
2.3 Scoring the drugs on the criteria 
The group agreed a hierarchy of evidence quality to assess data for the model in the following 
order: Firstly; systematic reviews, meta-analyses and, randomised controlled trials.  
Secondly, where the evidence was not definitive or unclear, cohort studies, case-control 
studies and cross sectional surveys were assessed, along with data from the UK summary of 
product characteristics (SPC). 
In situations where the evidence and SPC were not clear or not comparable, clinical judgment 
by the independent academic experts took preference. 
Inputs for pain relief, duration of action, speed of onset and skin reactions are expressed in 
natural, measured units (table 1).  The group directly assessed preference values of 0 to 100 
for the other effects after discussing available data and, where necessary, pooling multiple 
sources of data subjectively.  
Hiview3 converted these measured units linearly into preference values, with the least and 
most preferred drug for each effect assigned preference values of 0 and 100, respectively.  As 
reliable data for the remaining seven unfavourable effect were unavailable, the group directly 
assessed preference values on 0 to 100 scales, which represented participants’ consensus 
about relative strengths of preference.  In constructing these judgements, participants 
discussed available data, and considered their experience and knowledge of how the drug acts 
on the body, pooling these multiple sources of information subjectively.  
[Insert Table 1 about here]. 
2.4 Weighting of the criteria  
Some criteria are more important expressions of benefit or risk than others, (e.g. minor GI 
effects versus anaphylaxis), so weighting of the criteria was required. The purpose of 
weighting is to ensure that the units of relative benefits and risks on different scales are 
equivalent, thus enabling weighted scores to be compared and combined across the criteria.   
To assess weights that are meaningful in MCDA, it was necessary to consider the differences 
in effects between highest and lowest scoring products on that criterion, and to establish how 
much that difference in effect matters in a given context, or in other words ‘how big is the 
difference and how important is it’   
Weights were elicited in the decision conference by asking the experts to compare the swing 
in preference from the least preferred drug on a given effect to the most preferred, as 
compared to the swing on another effect.  For example, the swing on pain relief from aspirin 
to ibuprofen S&S was judged to be greater than the swing on duration of action from 
paracetamol to naproxen.  
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The weighted scores for each analgesic were summed to give an overall index of the benefit-
risk ratio.  Hiyiew calculated the weighted scores and provided displays of the results. 
Sensitivity analyses were also performed using Hiview3 by varying the weightings of the 
effect criteria to see how the overall results might change.  
2.5 Peer review process: 
To further validate the output and ensure that a robust interpretation of the data was 
performed, the authors completed a peer review exercise on 3 March 2015 to examine the 
quality and clinical interpretation of the data entered into the MCDA model.   This involved 
inviting 5 European experts (see acknowledgements) to review the data, scores, and weights 
that had been input into the MCDA model. The peer reviewers also debated issues and again 
reviewed the model outputs during a face-to-face half-day meeting.  This also allowed 
additional sensitivity analyses to be performed by comparing the scores of the drugs before 
and after the peer-review process. 
3. Results: 
The final weighted preference scores, before and after peer review, are presented graphically 
in Figure 2. The peer-review process confirmed ibuprofen S&S as the most preferred OTC 
analgesic for its benefit-risk ratio, and aspirin at least preferred.  The Pearson correlation 
coefficient between these scores is 0.91. 
[Insert Figure 2 about here] 
During the peer-review process, a small change in the score on the adverse reaction for GI 
effects, from 100 to 90, and major changes to scores on serious adverse reactions for GI 
effects and overdose toxicity were introduced. While these changes did not affect the ranking 
of ibuprofen S&S, naproxen sodium or ibuprofen acid, they increased the overall weighted 
preference score of diclofenac from 31 to 54, moving it from fifth place in the ranking to 
fourth place, close to the score for ibuprofen acid of 57.  The overall score for paracetamol 
remained at 39, followed by aspirin, whose score decreased from 28 to 13. The original 
experts accepted these changes and the results. 
The six drugs differed from one another in various ways, as can be seen by the varying sizes 
of the coloured sections of the bar chart in Figure 3.  The cumulative weights for the effects 
(normalised to sum to 100, but preserving their original ratios) are shown.  Ibuprofen S&S 
remained the most preferred of these six, as it scored 100 on 3 of the most heavily weighted 
effects (overdose toxicity, pain relief and speed of onset).  In addition, ibuprofen S&S as can 
be seen from Figure 3 was overall more beneficial and better tolerated than the others, so it 
remained the most preferred for any relative weights between favourable and unfavourable 
effects. 
[Insert Figure 3 about here] 
Comparing the weighted preference scores of pairs of drugs, one with another, showed the 
relative advantages of each drug in the pair.  For example, ibuprofen S&S compared with 
paracetamol (Table 2) showed better pain relief, longer duration of action and faster speed of 
onset, with less overdose toxicity.  Other quantitative comparisons showed that ibuprofen 
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S&S compared with naproxen was better for overdose toxicity, pain relief, speed of onset and 
serious GI effects, while naproxen sodium was better for duration of action. Comparisons of 
all six drugs, taken two-at-a-time, i.e.15 paired-comparisons, were consulted in drafting the 
text summaries of each drug shown in table 3.  It is this kind of summary that might be most 
useful to clinicians. 
[Insert Table 2 about here] 
 
[Insert Table 3 about here] 
Changing weights over their possible range from 0 to 100 revealed the extent to which the 
results are sensitive to the imprecisions in judging weights on the effects criteria.  Multiple 
sensitivity analyses examining variations in the weight of each factor, particularly serious 
adverse reactions, serious CV effects, anaphylaxis and overdose toxicity, showed that only 
substantial changes in weights would lead to an analgesic other than ibuprofen S&S as the 
most preferred drug (Figure 4). Sensitivity analyses showed that the order of preference 
scores for the drugs did not change over very large ranges for the individual weights. Results 
from the MCDA model were robust to changes in weights of the criteria and the nodes.  
[Insert Figure 4 about here] 
4. Discussion:  
Information about analgesics for OTC doses and duration of use is limited. While clinical 
trials exist either with placebo or against an active comparator, these are typically of single 
doses over hours [14]. Studies have not specifically been conducted to assess the benefit-risk 
balance of OTC analgesics.  OTC analgesics are considered to be safe and effective, almost 
by definition: if a positive benefit-risk profile had not been rigorously demonstrated then 
these products would not be approved for OTC use, typically at lower doses in the short term.  
Most of the existing evidence underpinning analgesic use derives from knowledge and 
clinical experience with prescription analgesics used at higher doses and for prolonged 
periods.  In making benefit-risk assessments we have only lower-dose short-term efficacy 
data, and higher-dose long-term adverse event and risk data. The challenge is to find a way to 
use these disparate data sources to make a judgement. MCDA offers a way forward for OTC 
analgesics, and we have tested the method here for 6 OTC analgesics. 
The MCDA process provides a structured framework within which we can examine the many 
different aspects of making a specific judgement based on those aspects of efficacy and safety 
that are considered important. There are three stages – deciding what is important, rating the 
evidence for each aspect for each drug, and then ensuring that the output of the MCDA model 
make sense.  
But we did not rely solely on our own judgements. It was important to reality-and-fact-check 
the evidence used and judgements made by submitting our work to a separate panel of 
independent academics with an even broader experience of analgesic efficacy and safety. 
This process made small amendments to our judgements, resulting in no major change to the 
results of the MCDA analysis. The use of an independent panel improves quality control and 
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ensures that no important factors or knowledge are being omitted from the decision analysis 
process. Alternatively, we might originally have chosen for our first meeting a larger panel of 
experts; some research suggests that groups above about six in size do not add much accuracy 
[21]. 
An overall summary of the assessments that were obtained following the final peer-review 
process is shown in Table 3. These assessments prove a practical means of selecting the safer 
or more effective drugs amongst those that were examined in this study.   
The results of our MCDA analysis showed that, at typical OTC doses, fast-acting 
formulations of NSAIDs were more favourably assessed, namely ibuprofen S&S, naproxen 
sodium, ibuprofen acid and diclofenac potassium over paracetamol and aspirin. Evidence 
published since the MCDA panel met in 2014 reinforces the case for NSAIDs over 
paracetamol [22-28]. It is noteworthy that in the UK the National Institute for Health and 
Care Excellence (NICE) “identified reduced effectiveness of paracetamol in the management 
of OA compared with what was previously thought” [29], though the ultimate outcome of the 
discussions following this led to paracetamol being reinstated as first-line treatment [30]. 
Various steps are being taken in the USA to cut risks from paracetamol [31].  
The cardiovascular risk associated with the use of NSAIDs has been the source of 
considerable research. The very large CNT (Coxib and traditional NSAID Trialists')  analysis 
of randomised trials concluded that using NSAIDs at high doses in (mainly) arthritis trials 
was associated with a small increased risk of all-cause mortality, by about 20% compared 
with placebo [32], though the number of events with placebo was small. Subsequent 
observational studies have come to differing views, with some reporting increased event rates 
with NSAIDs and others, especially long-term longitudinal studies, reduced events [33]. The 
problem is that people with chronic pain have increased rates of cardiovascular disease and a 
20% increased all-cause mortality in any event [34]. A major factor usually ignored is the 
negative effect of mobility in chronic pain conditions; lack of mobility tends to increase 
mortality in chronic pain [35]. These confounding factors are not often considered. 
A recent study suggested an increased risk of heart failure with NSAIDs in a dose-dependent 
manner and called for further research into the safety of OTC NSAIDs [36]. The 
accompanying editorial suggested that paracetamol or weak opiates might be good choices 
without giving any consideration to their benefit-risk balance, and that more restricted 
policies on the availability of NSAIDs by regulatory authorities is warranted [37]. Our 
MCDA has demonstrated that fast-acting formulations of NSAIDs used over short periods at 
low doses have better overall benefit-risk profiles compared to paracetamol, and highlights 
the importance of a comprehensive and balanced assessment of benefits and risks, rather than 
focusing primarily on risks and mitigation of those risks.  
5. Conclusions 
The MCDA model described by Keeney and Raiffa [38] , is a useful tool for comparison of 
multiple favourable and unfavourable effects, data types and clinical judgments in a single 
model. It provides a framework that enables objective and reproducible benefit-risk 
assessment.  Output is comprehensible to physicians, pharmacists, and other health 
professionals. 
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This analysis indicated that amongst the most common six simple OTC analgesics, ibuprofen 
S&S is associated with the most favourable benefit-risk profile, mainly owing to its low 
overdose toxicity, good pain relief, and fast onset of action. It is closely followed by 
naproxen sodium which performed somewhat less well on pain relief, speed of onset and 
overdose toxicity, but better on duration of action. Fast-acting OTC Non-Steroidal Anti-
inflammatory drugs (NSAIDs) are associated with more favourable benefit- risk profiles 
compared with paracetamol.  
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Figures and Tables: 
 
Figure 1: The final Effects Tree 
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Figure 2 - Overall weighted preference scores before and after peer-review 
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Figure 3 - Overall weighted preference scores with separate contributions shown for each effect.  Longer 
segments for favourable effects indicate more benefit, while longer segments for unfavourable effects show 
greater safety 
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Figure 5: Sensitivity analysis for Unfavourable Effects 
 
  
Total weight on unfavourable effects 
Figure 4: Sensitivity analysis for Unfavourable Effects 
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Table 1: Effects table highlighting the data inputs into the model. The first four rows are measured data, 
and the remaining rows are preference judgements. 
Effects Units Ibuprofen 
acid 
Ibuprofen 
S&S 
Paracetamol Diclofenac Aspirin Naproxen 
sodium 
Favourable Effects 
Pain relief % 48 63 33 45 20 55 
Duration of 
action 
hours 5.5 7 4 4.5 5 9 
Speed of 
onset 
mins. 55 27 30 45 50 30 
Unfavourable Effects 
Adverse Reactions 
Skin 
reactions 
N
o
. 24 24 77 41 124 26 
GI safety Pref. 100 100 100 100 0 100 
Hepatic 
safety 
Pref. 100 100 0 100 30 50 
Serious Adverse Reactions 
GI safety Pref. 40 50 100 30 0 20 
CV safety Pref. 75 75 75 0 100 80 
Renal safety Pref. 100 100 100 100 100 0 
Anaphylaxis Pref. 50 50 100 50 0 50 
Overdose 
Toxicity. 
Pref 100 100 0 0 75 75 
Note on units in the table:  These are as presented in clinical studies.  
Some as percentages and others as actual numbers of incidents.  Times as 
hours or mins (minutes), are mean times.   
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Table 2: Ibuprofen S&S compared to paracetamol.  Green bars show the size of advantages of ibuprofen 
S&S, while red bars show the size of ad 
 
  
Use of MCDA for assessing the Benefit and Risk of OTC Analgesics 
 
 pg. 16 
 
Table 3: Summary of Main Outcomes of Assessment of Benefits and Risks of Over-the-counter (OTC) 
analgesics 
Ibuprofen soluble 94 
 
FAVOURABLE EFFECTS 
Shows best pain relief and 
speed of onset (27 
minutes). Only naproxen 
shows longer duration of 
action.  
UNFAVOURABLE EFFECTS 
Safer than naproxen and 
aspirin for serious GI 
effects, which are about the 
same as diclofenac and 
worse than paracetamol. 
Both forms of ibuprofen are 
lowest for overdose 
potential. 
 
Naproxen 83 
 
FAVOURABLE EFFECTS 
Longest duration of action 
(9 hr; compared with 7 hr 
for soluble ibuprofen, & 4hr 
for paracetamol. Speed of 
onset, 30 minutes, is about 
the same as soluble 
ibuprofen. 
UNFAVOURABLE EFFECTS 
The incidence and severity 
of serious GI effects is more 
than aspirin but less than 
the other drugs. 
 
Ibuprofen tablet 57 
 
FAVOURABLE EFFECTS 
Pain relief is more than 
diclofenac, paracetamol and 
aspirin. Longer duration of 
action than diclofenac, 
paracetamol and aspirin  
UNFAVOURABLE EFFECTS 
This tablet form of 
ibuprofen shares with 
soluble ibuprofen the 
lowest potential for 
overdose. 
 
Diclofenac 54 
  
FAVOURABLE EFFECTS 
More than paracetamol and 
aspirin for pain relief and 
has a faster speed of onset 
than ibuprofen tablets and 
aspirin. 
UNFAVOURABLE EFFECTS 
Diclofenac has comparable 
serious GI effects with 
naproxen and less than 
aspirin. Low potential for 
overdose. 
 
Paracetamol 39 
 
FAVOURABLE EFFECTS 
The 30-minute speed of 
onset of this drug and 
naproxen is slightly slower 
than soluble ibuprofen at 27 
minutes, but at least 15 
minutes better than any of 
the others. Better than 
aspirin for pain relief. 
UNFAVOURABLE EFFECTS 
It is the safest drug for 
serious GI effects, but has 
the highest potential for 
overdose. 
 
Aspirin 13 
 
FAVOURABLE EFFECTS 
Speed of onset (50 min) 
comparable with ibuprofen 
(50 min); duration of action 
(5 hr), longer than 
paracetamol’ (4hr) or 
diclofenac (4.5 hr). 
UNFAVOURABLE EFFECTS 
Aspirin has lower potential f 
than paracetamol for 
accidental or deliberate 
overdose. 
 
The bold numbers are overall weighted preference values out of 100, which take into 
account available data for the effects, and judgements of the experts about the clinical 
relevance of the effects. They do not take account of contra-indications, interactions with 
other drugs, or other precautions. Figures given in the descriptions are averages; individuals 
may experience effects that are different from these averages. 
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Appendix 1.  Multi-Criteria Decision Analysis 
 
Multi-criteria decision analysis (MCDA) is an eight-step methodology for determining the overall 
ordering of options that differ on many criteria.  The MCDA approach provides a theoretically 
sound way to compare apples and oranges by comparing, within a given context, their preference 
value, a metric that is not monetary, but can include financial criteria.  MCDA combines hard 
data with informed judgement about preference values, distinguishes between facts and value 
judgements, and accommodates risk, uncertainty, and multiple, conflicting objectives.  
Most multi-criteria approaches are characterised by a process of scoring the preference values of 
options (projects, programmes, policies, strategies, systems, etc.) on the evaluation criteria, 
weighting the criteria to ensure common units of preference value across the criteria, and then 
summing the weighted scores to provide an overall ordering of the options.  The various forms 
of multi-criteria analysis are briefly reviewed in Dodgson, Spackman, Pearman and Phillips [1]], 
and explained in detail by Belton and Stewart [2].  Dodgson et al felt that the most appropriate 
approach for policy development in the UK was MCDA.   Their selection was guided by the 
firm grounding of MCDA in decision theory, whose axiomatic base [3, 4] leads to expected 
utility theory as the guiding principle for choosing between courses of action.  The foundations 
for an applied theory of decision making appeared with the publication of a text by Raiffa & 
Schlafer[5].  Simultaneous developments on the west and east coasts of the United States led to 
establishing decision analysis as the theory’s applied technology [6, 7].  Later, decision theory was 
expanded to include decisions with multiple objectives [8].  By extending the axioms of coherent 
choice, they showed how multiple, conflicting objectives could be included in the analysis, along 
with uncertainty and risk. 
An MCDA model is often created in a facilitated workshop attended by key players who 
represent the various perspectives on the issues.  This project applied the type of facilitated 
workshop known as a decision conference [9], in which the impartial facilitator guides the 
process of creating a model, while the leader and participants contribute the content.  This 
separation of responsibility for process from content makes possible the rapid development and 
exploration of the model, which usually is completed in one to three days, though refinements 
may well take place subsequently for complex problems, often in a series of workshops. 
It is important to recognise that the overall purpose of an MCDA is to provide a guide to action, 
not to give ‘the right answer’.  An MCDA model helps to stimulate creative thinking, deepens 
insight, and lends structure to thinking.  Some critics have objected that MCDA is just a process 
of collecting opinions and personal judgements, disqualifying it from being considered a proper 
scientific approach.  In fact, taking a complex problem apart into its decision-theoretic pieces 
(options, criteria, preference scores, and criteria weights) enables experts collectively to discuss 
and make judgements about the elements, and for the ‘logical glue’ of the weighted value rule to 
combine the pieces, resulting in a model that represents the current state of knowledge and 
judgement of a collection of experts. 
Bias is eliminated or minimalised in the decision conference by impartial facilitation, which helps 
to legitimise information and to ensure that all experts have their say.  Participants are chosen to 
represent the diversity of opinion about the topic, and peer review is most vigorous at the stage 
of scoring and weighting, as participants express their judgements as numerical values.  It is 
common for experts to disagree, but assigning numbers often reveals differences in perspective 
that reflect each person’s past experience.  Sharing that experience in the decision conference 
provides a degree of learning that enables a model to be constructed.  The point is to create a 
model that contributes to the reliability and validity of the final results. 
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Appendix 2.   Summary of Data Sources 
Table 1: Data Summary Efficacy 
 Ibuprofen 
soluble 
400 mg 
Ibuprofen 
acid  
400 mg 
Paracetamol 
1000 mg 
Diclofenac 
K 
25 mg 
Naproxen 
Sodium 
400/440 
mg 
ASA  
600/650 mg 
NNT 2.1 2.5 3.2 2.6 2.7 4.5 
Ref Bandolier website: 
http://www.medicine.ox.ac.uk/bandolier/booth/painpag/acutrev/analgesics/leagt
ab.html [1] 
Moore RA, Derry S, Straube S, Ireson-Paine J and Wiffen PJ (2014) Pain 155:14-
21 [2] 
Onset 
(min) 
<20 20-40 20 Same as 
para 
>30 <20 
Ref Daniels 
2009[3] 
Desjardin
s 2002[4] 
Mehlisch 
2013[5] 
Desjardin
s 2002[4] 
Daniels 
2009[3] 
Moore N 
2007b [6] 
Sevelius 
[7] 
Disprin 
Monograph 
Duration 
(h) 
8 8 5 4-6 12 >5 
Ref Daniels 
2009 
[3]Kellstei
n 2000 
Malmstro
m [8, 
9]1999/20
04 Forbes 
1994 [10] 
Daniels 
2009 [3] 
Derry 
2009 [11] 
Moore N 
2007b [6] 
 Disprin 
Monograph 
 
 
Table 2: Data Summary Safety – GI, CV and Renal 
 Ibuprof
en 
soluble 
400 mg 
Ibuprofe
n acid  
400 mg 
Paracetam
ol 
1000 mg 
Diclofenac 
K 
25 mg 
Naproxen 
Sodium 
400/440 mg 
ASA  
600/650 
mg 
GI Relative 
Risk 
0.25-2.0 1-2.5  2-4 2.0-7.0 2.0-6.0 
Refs Lewis 2002 [12] , Hernandez-Diaz, 2000 [13], Moore 2003 [14], soluble 
ibuprofen ref: Gisbert 2005 [15], Hawkey 2012 [16], Muller & Simon 1994[17] 
CV 
Relative 
Risk 
0.9-1.2 1.0-1.72 0.7-2.6 0..2-2.5 0.72-
1.11 
 Ibuprof
en 
soluble 
400 mg 
Ibuprofe
n acid  
400 mg 
Paracetam
ol 
1000 mg 
Diclofenac 
K 
25 mg 
Naproxen 
Sodium 
400/440 mg 
ASA  
600/650 
mg 
Refs Jick 2006 [18], 
McGettigan & Henry 
2006 [19] 
Chan 
2006[20] 
Jick 2006 
[18], 
McGettigan 
& Henry 
2006 [19] 
Jick 2006 
[18], 
McGettigan 
& Henry 
[19] 
Chan 
2006[20
] 
Renal 
frequency 
Very rare Very 
rare 
Very rare uncommon Very 
rare 
Refs Joint Formulary Committee. British National Formulary (online) London: BMJ 
Group and Pharmaceutical Press <http://www.medicinescomplete.com>; 
Martindale: The Complete Drug reference 
<http://www.medicinescomplete.com> 
 
 
Table 3: Data Summary Safety – Rare Events 
 Ibuprofen APAP  
1000 mg 
Diclofenac 
K 
25 mg 
Naproxen 
Sodium 
400/440 mg 
ASA  
600/650 mg 
 soluble 
400 mg 
acid  
400 mg 
Hepatic 
frequency 
Very rare O/D risk 
with ≥ 5g  
Very rare Very rare uncommon 
Ref British National Formulary (online) London: BMJ Group and Pharmaceutical Press 
<http://www.medicinescomplete.com>; [21] Martindale: The Complete Drug reference 
<http://www.medicinescomplete.com>[22] 
Hypersensitivity 
frequency 
uncommon rare rare uncommon hypersensitivity 
with asthma, 
chronic rhinitis 
or chronic 
urticaria 
Ref British National Formulary (online) London: BMJ Group and Pharmaceutical Press 
http://www.medicinescomplete.com [21]; Martindale: The Complete Drug reference 
<http://www.medicinescomplete.com>[22] 
 Ibuprofen APAP  
1000 mg 
Diclofenac 
K 
25 mg 
Naproxen 
Sodium 
400/440 mg 
ASA  
600/650 mg 
 soluble 
400 mg 
acid  
400 mg 
Overdose and 
toxicity 
Symptoms of nausea, 
vomiting, epigastric 
pain, and tinnitus have 
been reported after 
ibuprofen overdosage. 
More serious toxicity is 
uncommon  
can 
result in 
acute 
liver 
damage 
and 
tubular 
renal 
necrosis 
As for 
other 
NSAIDs 
As for other 
NSAIDs 
Symptoms of 
dizziness, 
tinnitus, 
deafness, 
nausea, 
sweating, 
vomiting, 
headache and 
confusion 
reversed on 
cessation of 
treatment 
Ref Martindale: The Complete Drug reference <http://www.medicinescomplete.com>[22] 
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